Autres langues Immunocore Holdings plc

Actions

IMCR

US45258D1054

Marché Fermé - Nasdaq Autres places de cotation 21:59:47 04/06/2024			Varia. 5j.	Varia. 1 janv.
43,29 ^USD	+1,29 %		-6,50 %	-36,64 %

01/06	Immunocore Holdings plc présente les données cliniques de KIMMTRAK démontrant que les patients dont la maladie est stable et la réduction tumorale confirmée ont des résultats cliniques similaires à ceux des patients présentant une réponse partielle.	CI
01/06	Transcript : Immunocore Holdings plc - Special Call

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	01/06
Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	01/06
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	01/06
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024	31/05
Immunocore Holdings plc Reports Updated Phase 1 Data of Brenetafusp (IMC-F106C), an ImmTAC Bispecific Targeting PRAME, in Immune Checkpoint Pre-treated Cutaneous Melanoma Patients at ASCO 2024	31/05
Immunocore to present at the Jefferies Global Healthcare Conference	30/05
Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3	29/05
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma	29/05
Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma	29/05
Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director	28/05
Immunocore Holdings' Shares Fall After Q1 Net Loss Widens	08/05
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS Reports Q1 Revenue $70.5M	08/05
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Immunocore reports first quarter financial results and provides a business update	08/05
Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	01/05
Immunocore announces upcoming presentation and posters at ASCO 2024	24/04
Immunocore to present at upcoming investor conferences	04/04
Immunocore Holdings Files Mixed-Securities Shelf Registration	21/03
Immunocore presented two posters at CROI 2024	05/03
Immunocore to present at upcoming investor conferences	01/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Immunocore Holdings plc

Actions

IMCR

US45258D1054

Autres langues

Filtres